Progyny, Inc. PGNY
PGNY is a $3.1bn fertility-benefits manager run by ex-WebMD/Medical Manager executives whose marketing claims, treatment model and 2023 growth are disputable, implying 60%-80% downside to $7-$14.
Thesis
Spruce Point argues Progyny is a Strong Sell with 60%-80% downside to $7-$14 per share. The top three PGNY executives and a director all held senior roles at Medical Manager/WebMD when a 16-executive accounting fraud unfolded, and Spruce Point sees echoes in PGNY's forensic red flags: spiking unbilled receivables, disparity between reported Adjusted EBITDA and operating cash flow, and questionable client/member disclosures. The firm contends PGNY's 'superior outcomes' marketing is methodologically flawed, its direct-to-IVF and preimplantation genetic testing protocols serve revenue rather than science, and its treatment mandates may violate corporate practice of medicine laws. Combined with a commoditizing competitive landscape (Kindbody, Carrot, Maven, WIN), rising CAC, maturing utilization, and pharmacy-price tailwinds rolling off, Spruce Point projects 2023 consensus is too high and insiders have cut their stake from 52% pre-IPO to 14%.
SCQA
Progyny is a $3.1bn Nasdaq-listed fertility benefit manager that sells a structured fertility insurance benefit to self-insured employers, mostly large tech firms, and has grown to over $700m in LTM revenue since its 2019 IPO.
The top three executives and a director previously held senior roles at Medical Manager/WebMD during a 16-executive accounting fraud, and PGNY now exhibits forensic red flags, disputable outcomes marketing, a revenue-maximizing IVF/PGT protocol, and intensifying competition.
Sell PGNY: reject management's outcomes claims and growth story, apply a discounted healthcare multiple to a realistic Adjusted EBITDA that adds back stock-based compensation, and recognize that 2023 consensus revenue and EBITDA estimates are too high.
Spruce Point's fair value price target is $7 to $14 per share, representing approximately 60% to 80% downside from the $33.43 closing price on February 6, 2023.
The three reasons
- 1
Top PGNY executives held senior roles at Medical Manager/WebMD during a 16-executive accounting fraud
- 2
PGNY's 'direct to IVF' model and PGT push maximize revenue but lack scientific support
- 3
Competitive commoditization, client churn and utilization headwinds make 2023 consensus unachievable
Primary demands
- Investors should sell PGNY shares given 60%-80% downside risk
- Scrutinize management team's prior association with Medical Manager/WebMD accounting fraud
- Question PGNY's disputable outcomes marketing claims and treatment model conflicts of interest
- Reassess consensus 2023 revenue and EBITDA estimates given mounting headwinds
KPIs cited
Pattern membership
Precedents cited
- Medical Manager / WebMD accounting fraud (2005 DOJ indictments)
- Spruce Point FIGS short (2022)
- Spruce Point HESKA short (2021)
- Spruce Point PETQ short (2019)
- Spruce Point C3.ai short
- Spruce Point Leidos (LDOS) short
Composition what's on the 100 slides
Slide gallery ·
Notes
Classic Spruce Point short-report format: evocative cover illustration ('Scientific Truth' boulder pushed uphill by clinicians toward 'Progress' sign), dense legal disclaimer, track-record slide (FIGS/HESKA/PETQ), SCQA opener on page 6, then 90+ pages of forensic, competitive, scientific and valuation arguments. Strongest rhetorical devices: (1) the Medical Manager fraud org chart on p.15 visually color-coding indicted executives vs. current PGNY executives; (2) the 'Sarah' before/after reframing on p.86 turning PGNY's own marketing deck against itself; (3) the IVF-vs-IUI cost/efficacy table on p.87. Document is primary material authored by Spruce Point. Campaign phase coded as initial_thesis: although a prior unnamed bearish report existed on PGNY, this is Spruce Point's own first public thesis on the name.